M100A×M100B-vedotin

M100A×M100B-vedotin is a next-generation biparatopic antibody-drug conjugate (ADC) developed by GO Therapeutics. It targets two distinct tumor-specific Tn-glycoepitopes on the Mucin-1 (MUC1) protein, which are neoepitopes generated by altered O-glycosylation in epithelial cancers and are largely absent from healthy tissues. The ADC is engineered as a site-specific conjugate with a drug-to-antibody ratio (DAR) of 2, utilizing an mc-vc-PAB linker to deliver the cytotoxic payload monomethyl auristatin E (MMAE). By binding two different epitopes on MUC1, the drug increases avidity and overcomes epitope heterogeneity within tumors. Preclinical studies presented at AACR 2026 demonstrated potent cytotoxicity and significant tumor regression in models of breast, lung, ovarian, pancreatic, and gastrointestinal cancers, while maintaining a favorable safety profile.

Other names

Tn-MUC1 biparatopic ADCTn-MUC-1 biparatopic ADCTn-MUC 1 biparatopic ADCMUC1 biparatopic ADCMUC-1 biparatopic ADCMUC 1 biparatopic ADC